Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Navidea Biopharmaceuticals Inc
(NY:
NAVB
)
0.0779
UNCHANGED
Last Price
Updated: 8:00 PM EDT, Oct 5, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Navidea Biopharmaceuticals Inc
< Previous
1
2
3
Next >
Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Program
December 15, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Terminates Stock Purchase Agreement
December 15, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis
December 13, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition
December 09, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results
November 10, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update
November 03, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin
October 26, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors
October 14, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer
September 27, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition
September 17, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results
August 11, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update
August 04, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications
July 19, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis
July 15, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty
June 24, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections
May 19, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results
May 11, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent
May 11, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition
May 05, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals to Host First Quarter 2021 Earnings Conference Call and Corporate Update
May 04, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
Navidea Biopharmaceuticals Announces Acceptance of Therapeutics Focused Abstract for Presentation at the Frontiers in Cancer Immunotherapy Symposium
April 15, 2021
From
Navidea Biopharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.